May 7, 2024 7:44am

After 1 mixed, 3 market and 4 sector upside closes; are they about to cruise to a bruising? 

Earnings - Today: Beam Therapeutics (BEAM), Ionis Pharmaceuticals (IONS), uniQure NV (QURE) and Agenus (AGEN)

Pre-open Indications: 1 Sell into Strength and 4 Negative Indications

I am right more often than not and investors have always been able to count on … RMi for return on investment (ROI); start thinking return on speculation

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RMi.

 

Monday: The pre-open Dow futures are UP +0.07% or (+28 points), the S&P futures are UP +0.02% or (+1 pints) as the Nasdaq futures are DOWN -0.20% or (-36 points)

U.S. stock futures were mixed and inching around the flatline Tuesday,

European markets had a positive start to trading,

Asia-Pacific markets were mixed, up, down and flat

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Monday: The Dow closed UP+156.59 points or +0.46%, the S&P closed UP +52.95 points or +1.03% while the Nasdaq closed UP +192.92 points or +1.19%

Economic Data Docket: quiet week for econ data with Consumer Credit expected

 

Monday night’s RegMed Investors (RMi) Closing Bell: “they’re coming – earnings this week: Ionis Pharmaceuticals (IONS), Agenus (AGEN) on Tuesday, 5/7, Editas Medicine (EDIT), Vericel (VCEL), Lenz Therapeutics (LENZ) on Wednesday, 5/8; BioLife Solutions (BLFS), blue bird bio (BLUE), Fate Therapeutics (FATE), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO) on Thursday, 5/9. Let’s not forget about volatility.” … https://www.regmedinvestors.com/articles/13448

 

Q2/24:  May – 4 positive closes

  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength:

Monday, Friday, Thursday, Wednesday and last Tuesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Voyager Therapeutics (VYGR +$0.13 after Friday’s +$0.28 with a neutral pre-open indication.

 

Negative indications:

Monday, Friday, Thursday, Wednesday and last Tuesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Agenus (AGEN) closed down -$0.12 after Friday’s +$0.55, Thursday’s -$0.74, Wednesday’s +$1.14, and last Tuesday’s -$0.64 with a neutral pre-open indication.

Beam Therapeutics (BEAM) closed down -$0.35 after Friday’s +$0.41 after Thursday’s +$0.98 with neutral pre-open indication.

Blueprint Medicine (BPMC) closed down -$0.94 after Friday’s +$0.19, Thursday’s +$12.14, Wednesday’s +$3.64 and last Tuesday’s -$1.76 with a neutral pre-open indication. Also, hit a 52-week high.

CRISPR Therapeutics (CRSP) closed up +$1.17 after Friday’s +$0.82, Thursday’s +$1.26, Wednesday’s +$0.82 and last Tuesday’s -$1.84 with a negative -$0.10 or -0.18% pre-open indication.

 

The BOTTOM LINE: “if one watches the flow, the numbers and understanding the old Abbot & Costello monologue: Who’s on first, what’s on second and I don’t know who is on third – that’s what I want to find out!”

  • Q4 earnings LPS (loss-per-share), “runways”, news and financings, will be the under-current or headwind for May through June 2024. Pricing for gene therapies will continue to dominate share ascensions and downfalls!

Also, sentiment seems to be slipping. My question, are we facing a prisoner’s dilemma- a situation wherein algorithms acting with electronic trading interest do not achieve the optimal outcome for this investor group

  • Drip, drip, drip from last to this week’s sessions = 6 to 9 to 12 to 15 equities dropping, watch for the drips going forward …

Spare the sell call, ruin the portfolio

  • “I hate to be negative or contrarian but, this is a NO spin zone and pricing truth is its product; I can always be WRONG but, I am mostly EARLY!”

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.